Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma: The possibility of its clinical use as a tumor marker and a target antigen in cancer immunotherapy

Cancer

Volumn 95, Issue 9, 2002, Pages 1954-1962

  Ozaki, Yoshitomo ^a   Kontani, Keiichi ^a   Hanaoka, Jun ^b   Chano, Tokuhiro ^a   Teramoto, Koji ^a   Tezuka, Noriaki ^a   Sawai, Satoru ^a   Fujino, Shozo ^a   Yoshiki, Tatsuhiro ^a   Okabe, Hidetoshi ^a   Ohkubo, Iwao ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

90K Mac 2 binding protein; Immunogenicity; Immunotherapy; Lung carcinoma; Tumor marker; Tumor associated antigen

Indexed keywords

BINDING PROTEIN; IMMUNOGLOBULIN G; MAC 2 BINDING PROTEIN; PROTEIN ANTIBODY; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; LUNG CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY;

AGED; AMINO ACID SEQUENCE; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BLOTTING, NORTHERN; CARRIER PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0036839704     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10899     Document Type: Article

References (43)

1. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1994;254:1643-1647.
2. Boel P, Wildmann C, Sensi ML, et al. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-175.
3. Boon T, Van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183:725-729.
4. Bakker AB, Schreurs MW, De Boer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-1009.
5. Shichijo S, Nakao M, Imai Y, et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998;187:277-288.
6. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-495.
7. Gendler SJ, Lancaster CA, Taylor -Papadimitriou J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286-15293.
8. Peoples GE, Goeegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci 1995;92:432-436.
9. Fisk B, Chesak B, Pollack MS, Wharton JT, Ioannides CG. Oligopeptide induction of cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. Cell Immunol 1994;157:415-427.
10. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.
11. Nestle FO, Alijiagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
12. Hanaoka J, Kontani K, Sawai S, et al. Analysis of MUC4 mucin expression in lung carcinoma cells and its immunogenicity. Cancer 2001;92:2148-2157.
13. Iacobelli S, Arno E, D'Orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 1986;46:3005-3010.
14. Iacobelli S, D'Egidio M, Giuliani C, et al. Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines. FEBS Lett 1993;319:59-65.
15. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem 1993;268:14245-14249.
16. Ullrich A, Sures I, D'Egidio M, et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem 1994;269:18401-18407.
17. Natoli C, Iacobelli S, Kohn L. The immune stimulatory protein 90K increases major histocompatibility complex class I expression in a human breast cancer cell line. Biochem Biophys Res Commun 1996;225:617-620.
18. Iacobelli S, Arno E, Sismondi P, et al. Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. Breast Cancer Res Treat 1988;11:19-30.
19. Iacobelli S, Sismondi P, Giai M, et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer 1994;69:172-176.
20. Scambia G, Panici PB, Baiocchi G, Perrone L, Iacobelli S, Mancuso S. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. Anticancer Res 1988;8:761-764.
21. Iacobelli S, Natoli C, D'Egidio M, Tamburrini E, Antinori A, Ortona L. Lipoprotein 90K in human immunodeficiency virus-infected patients: A further serologic marker of progression. J Infect Dis 1991;164:819.
22. Natoli C, Iacobelli S, Ghinelli F. Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. J Infect Dis 1991;164:616-617.
23. Artini M, Natoli C, Tinari N, et al. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996;25:212-217.
24. Powell TJ, Schreck R, McCall M, et al. A tumor-derived protein which provides T-cell costimulation through accessory cell activation. J Immunother Emphasis Tumor Immunol 1995;17:209-221.
25. Kontani K, Taguchi O, Narita T, et al. Autologous dendritic cells or cells expressing both B7-1 and MUC1 can rescue tumor-specific cytotoxic T lymphocytes from MUC1-mediated apoptotic cell death. J Leukoc Biol 2000;68:225-232.
26. Kontani K, Taguchi O, Narita T, et al. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer 2001;84:1258-1264.
27. Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT. Glycoprotein 90K/Mac-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer 2001;91:167-172.
28. Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996;56:4530-4534.
29. Jallal B, Powell J, Zachwieja J, et al. Suppression of tumor growth in vivo by local and systemic 90K level increase. Cancer Res 1995;55:3223-3227.
30. Longo G, Natoli C, Rafanelli D, et al. Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. Br J Haematol 1993;85:207-209.
31. Kittl EM, Hofmann J, Hartmann G, et al. Serum protein 90K/Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection. Clin Chem Lab Med 2000;38:205-208.
32. Almasio PL, Di Marco V, Bonura C, et al. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. Dig Dis Sci 1999;44:1013-1019.
33. Groschel B, Braner JJ, Funk M, et al. Elevated plasma levels of 90K (Mac-2 BP) immunostimulatory glycoprotein in HIV-infected children. J Clin Immunol 2000;20:117-122.
34. Foekens JA, Klijn JG, Natoli C, et al. Expression of tumor-associated 90K-antigen in human breast cancer: No correlation with prognosis and response to first-line therapy with tamoxifen. Int J Cancer 1995;64:130-134.
35. Fusco O, Querzoli P, Nenci I, et al. 90K (Mac-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. Int J Cancer 1998;79:23-26.
36. Swissa M, Amital-Telizki H, Haim N, Cohen Y, Shoenfeld Y. Autoantibodies in neoplasia. An unresolved enigma. Cancer 1990;65:2554-2558.
37. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994;54:2856-2860.
38. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP. p53 antibodies in patients with various types of cancer: Assay, identification, and characterization. Clin Cancer Res 1995;1:1463-1469.
39. Soussi T. p53 antibodies in the sera of patients with various types of cancer. Cancer Res 2000;60:1777-1788.
40. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-3367.
41. Stockert E, Jager E, Chen YT, et al. A survey of humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-1354.
42. Jager E, Chen YT, Scanlan MJ, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-270.
43. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y. Cancer and autoimmunity: Autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001;60:433-440.